预约演示
更新于：2024-12-27
Desvenlafaxine succinate monohydrate
琥珀酸去甲文拉法辛
更新于：2024-12-27
概要
基本信息
药物类型 小分子化药 |
别名 Desvenlafaxine SR、DVS-SR、O-desmethylvenlafaxine + [9] |
作用机制 NET抑制剂(去甲肾上腺素转运蛋白抑制剂)、SERT抑制剂(5-羟色胺转运体抑制剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2008-02-29), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H25NO2 |
InChIKeyKYYIDSXMWOZKMP-UHFFFAOYSA-N |
CAS号93413-62-8 |
关联
80
项与 琥珀酸去甲文拉法辛 相关的临床试验ChiCTR2400092914
Efficacy and safety of Desvenlafaxine Succinate Sustained-release Tablets in Peri-menopausal and Postmenopausal Women with Major Depressive Disorder: A single-arm, Multicenter, Real-world Study
CTR20241827
琥珀酸去甲文拉法辛缓释片人体生物等效性研究
CTR20232944
琥珀酸去甲文拉法辛缓释片在中国健康受试者中单中心、随机、开放、单次给药、两制剂、两周期交叉人体生物等效性试验
100 项与 琥珀酸去甲文拉法辛 相关的临床结果
登录后查看更多信息
100 项与 琥珀酸去甲文拉法辛 相关的转化医学
登录后查看更多信息
100 项与 琥珀酸去甲文拉法辛 相关的专利（医药）
登录后查看更多信息
330
项与 琥珀酸去甲文拉法辛 相关的文献（医药）2024-11-01CHEMOSPHERE
Investigating the presence, distribution and risk of pharmaceutically active compounds (PhACs) in wastewater treatment plants, river sediments and fish
Article
作者: Martínez, María Ángeles ; Navarro, Irene ; Torre, Adrián de la ; Royano, Silvia
The increasing consumption of medicines and the lack of efficient technologies in wastewater treatment plants (WWTPs) can release pharmaceutically active compounds (PhACs) into any given river with the subsequent risk to the environment and human health. To assess the occurrence and transfer pathways of PhACs through the river ecosystem, 22 PhACs and one metabolite were analyzed in WWTPs, river sediments and fish collected alongside the Tagus River basin between 2020 and 2022. All the matrices presented at least two drugs being azithromycin the only one quantified in all of them. Analgesics, anti-inflammatories, antihypertensives, antidepressants and beta-blockers were the main PhACs in influents, with median concentrations up to 19 μg/L. In effluents, antihypertensives and antidepressants were the PhACs with the highest contribution. For acetaminophen, ibuprofen, ketoprofen, naproxen, atorvastatin, azithromycin, clarithromycin, sulfamethoxazole, trimethoprim, and valsartan WWTPs treatments reached removal efficiencies above 75%. Compounds with a high tendency to bind to organic matter were retained in sludge (clotrimazole, 96 ng/g before digester, 100%). However, results showed that applied treatments were not effective in removing PhACs from this matrix. Although the total mass balance revealed a high removal rate of some PhACs, many of them were still present in the effluent and their release into rivers became the main source of PhAC pollution of the aquatic ecosystem. The most hydrophobic ones (irbesartan, 24 ng/g, 61%), positively charged (o-desmethylvenlafaxine, 95 ng/g, 68%) and those with affinity to organic matter (clotrimazole, 21 ng/g, 61%) reached sediment samples. Only clotrimazole (7.8 ng/g) and azithromycin (160 ng/g) were found in fish samples. Risk assessment revealed a high risk for (i) acetaminophen, clarithromycin, erythromycin A, and venlafaxine in phototrophic organisms and (ii) acetaminophen and venlafaxine in fish.
2024-11-01SCIENCE OF THE TOTAL ENVIRONMENT
In-stream attenuation and enantioselective fractionation of psychiatric pharmaceuticals in a wastewater effluent-dominated river basin
Article
作者: Wang, Weimin ; Zhang, Hui ; Sun, Tao ; Jiang, Xiaoman ; Ma, Ning ; Xie, Tian ; Cui, Baoshan
Wastewater effluent is the main contributor of psychiatric pharmaceuticals (PPs) pollution in surface waters. However, little is known about its spatial evolution dynamics in effluent-dominated rivers. Herein, 10 representative PPs, including 6 chiral pharmaceuticals and 4 achiral pharmaceuticals, were explored in the Beiyun River, a typical wastewater effluent-dominated river, to explore their occurrence, in-stream attenuation and enantioselective fractionation behaviors at a watershed scale. Among the target substances, 8 and 9 drugs were detected in surface water and sediment samples with the ΣPPs concentrations ranging from 78.4 to 260.1 ng/L and 4.8 to 43.4 ng/g dw in surface water and sediments, respectively. Along the mainstream of the Beiyun River, only several PPs detected in surface water, e.g., citalopram, O-demethylvenlafaxine, and fluoxetine, exhibited in-stream attenuation behaviors when reaching rural area, while all PPs detected in sediments displayed in-stream attenuation behavior. Four chiral PPs detected in surface water exhibited an enantioselective attenuation phenomenon, while in sediments, only citalopram displayed an enantioselective fractionation behavior. The differences in the in-stream attenuation and enantioselective environmental behavior of individual PPs caused complex contaminant evolution along the stream reach. This work provides enantiomeric profiles of chiral pollutants for evaluating their in-stream attenuation processes, which would facilitate better understanding of the changing contaminant exposure conditions in complex natural environments.
2024-08-08PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY
Intranasal bilosomes in thermosensitive hydrogel: advancing desvenlafaxine succinate delivery for depression management
Article
作者: Nassar, Noha N. ; El-Nawawy, Tayseer M. ; Al-Samadi, Inas ; Nemr, Asmaa Ashraf ; Adel, Yomna A. ; El-Nabarawi, Mohamed A. ; Elhabal, Sammar F. ; Teaima, Mahmoud
Depression, the second biggest cause of disability worldwide, is widespread. Many antidepressant medications, including Desvenlafaxine Succinate (D.V.S.), function by elevating neurotransmitter levels at the synapse through the inhibition of reabsorption by neurons. However, the effectiveness of these treatments is often limited by their inability to reach the brain using conventional administration methods. Bilosome-stabilized nanovesicles containing bile salts have drawn much interest because of their adaptability and versatility in various applications. This study aimed to address this issue by formulating intranasal bilosomes incorporated into a mucoadhesive in situ gel to deliver D.V.S. directly to the brain for depression treatment. The desvenlafaxine-loaded bilosomes were developed using a thin film hydration method based on the l-optimal design. They were intended to provide a more convenient route of administration for antidepressants, enhancing bioavailability and brain targeting through intranasal delivery. The study assessed the optimized bilosomes for particle size (311.21 ± 0.42 nm), Zeta potential (-37.35 ± 0.43)and encapsulation efficiency (99.53 ± 0.41%) and further evaluated them in ex vivo and in vivo pharmacokinetics studies. Pharmacokinetic data reveal enhanced brain uptake compared to a free drug. A statistically optimized bilosome formulation was determined. The intranasal administration of mucoadhesive in situ gel containing desvenlafaxine succinate-loaded bilosomes facilitated direct nose-to-brain drug delivery, improving brain bioavailability.
100 项与 琥珀酸去甲文拉法辛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 潮热 | 墨西哥 | 2009-10-15 | |
| 抑郁症 | 加拿大 | 2009-03-05 | |
| 重度抑郁症 | 美国 | 2008-02-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中度重度抑郁症 | 临床3期 | 中国 | 2007-07-01 | |
| 中度重度抑郁症 | 临床3期 | 印度 | 2007-07-01 | |
| 中度重度抑郁症 | 临床3期 | 韩国 | 2007-07-01 | |
| 中度重度抑郁症 | 临床3期 | 中国台湾 | 2007-07-01 | |
| 纤维肌痛 | 临床3期 | 美国 | 2006-08-01 | |
| 糖尿病周围神经性疼痛 | 临床3期 | - | 2006-07-01 | |
| 糖尿病周围神经病变 | 临床3期 | 美国 | 2006-03-01 | |
| 疼痛 | 临床3期 | 美国 | 2006-03-01 | |
| 内因性睡眠障碍 | 临床3期 | - | 2004-09-01 | |
| 血管舒缩症 | 临床3期 | - | 2004-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 615 | Placebo (Placebo) | 鬱膚膚簾夢簾範鏇鏇構(蓋鹹齋淵壓顧簾製糧鬱) = 顧築廠鑰憲憲繭鏇獵襯 顧獵艱網廠艱獵鏇憲廠 (憲齋夢鬱獵簾鑰範夢膚, 鬱獵觸獵製膚獵顧鑰壓 ~ 遞鏇艱積襯網壓餘製襯) 更多 | - | 2024-02-29 | ||
(MD-120 50 mg) | 鬱膚膚簾夢簾範鏇鏇構(蓋鹹齋淵壓顧簾製糧鬱) = 蓋憲齋鹽淵獵壓鹹蓋選 顧獵艱網廠艱獵鏇憲廠 (憲齋夢鬱獵簾鑰範夢膚, 築憲艱簾衊願淵艱築積 ~ 膚齋鑰顧襯遞壓淵鬱廠) 更多 | ||||||
临床3期 | 363 | placebo (Placebo) | 廠範窪窪鹹遞餘憲醖壓(鬱糧觸簾網顧鏇糧鏇衊) = 醖簾鹽夢製窪廠鬱窪構 醖構遞鏇襯鬱鹹蓋醖蓋 (廠醖糧淵餘繭膚顧淵餘, 艱製築齋餘鬱簾鹹襯憲 ~ 淵襯鬱繭衊鹹膚願窪鬱) 更多 | - | 2017-03-20 | ||
(DVS SR Low Dose) | 廠範窪窪鹹遞餘憲醖壓(鬱糧觸簾網顧鏇糧鏇衊) = 願膚構壓窪鏇鹽願鏇遞 醖構遞鏇襯鬱鹹蓋醖蓋 (廠醖糧淵餘繭膚顧淵餘, 艱廠願壓壓獵築憲簾選 ~ 艱膚衊艱鑰鹽膚糧範鹽) 更多 | ||||||
临床3期 | 269 | Placebo (Placebo / DVS SR) | 壓網廠願艱範餘廠鏇簾(憲構壓範選鑰夢構鏇網) = 窪膚簾憲壓醖遞膚鹹鑰 製製獵窪鹹淵鹹夢窪選 (窪廠衊壓鏇選鏇膚範獵, 獵窪鑰壓遞壓範範鬱齋 ~ 醖積觸糧遞窪鹹構蓋繭) 更多 | - | 2017-02-08 | ||
DVS SR+Fluoxetine (Fluoxetine / DVS SR) | 壓網廠願艱範餘廠鏇簾(憲構壓範選鑰夢構鏇網) = 餘獵艱糧簾選簾選鑰蓋 製製獵窪鹹淵鹹夢窪選 (窪廠衊壓鏇選鏇膚範獵, 積鑰製獵願觸艱觸觸鹽 ~ 醖窪憲淵繭簾窪範繭壓) 更多 | ||||||
临床3期 | 283 | Placebo+DVS-SR (Placebo/DVS-SR) | 顧憲廠積網築製膚壓憲(網壓齋網齋齋蓋願獵願) = 鬱願構選範糧齋觸簾糧 膚積膚鏇壓築築壓製窪 (獵鹹廠簾製夢遞憲艱糧, 顧範壓膚鏇糧淵繭憲繭 ~ 積憲製繭願簾淵顧獵觸) 更多 | - | 2016-12-08 | ||
(DVS-SR, Low Dose/DVS-SR) | 顧憲廠積網築製膚壓憲(網壓齋網齋齋蓋願獵願) = 憲獵糧獵網憲積艱齋淵 膚積膚鏇壓築築壓製窪 (獵鹹廠簾製夢遞憲艱糧, 範淵獵夢壓窪夢鏇餘選 ~ 蓋齋網顧構積蓋鹹築艱) 更多 | ||||||
临床3期 | 340 | placebo (Placebo) | 淵築願艱範製積蓋壓夢(積糧願襯鹽繭選夢鬱簾) = 淵觸築觸願範範觸蓋積 壓獵窪遞窪夢衊遞鏇壓 (衊餘製蓋觸糧糧選觸選, 憲憲選鹽糧鑰襯遞蓋築 ~ 範憲簾壓構積糧醖選繭) 更多 | - | 2015-11-20 | ||
(Fluoxetine) | 淵築願艱範製積蓋壓夢(積糧願襯鹽繭選夢鬱簾) = 網鹽淵餘鬱窪製構壓獵 壓獵窪遞窪夢衊遞鏇壓 (衊餘製蓋觸糧糧選觸選, 淵觸鹽壓顧蓋齋選築夢 ~ 築壓淵糧醖鹽夢鹹繭窪) 更多 | ||||||
临床4期 | 63 | (Pristiq) | 構鏇鏇鏇製鏇願範鏇壓(鹹憲醖鑰淵鏇齋觸鏇構) = 積艱築鹹築窪築醖選窪 網襯願糧廠衊餘衊夢鹽 (淵鏇壓獵鹹膚選醖築淵, 憲窪餘衊齋淵簾廠鑰鹹 ~ 獵糧醖築壓觸糧齋構齋) 更多 | - | 2014-10-08 | ||
Placebo (Placebo) | 構鏇鏇鏇製鏇願範鏇壓(鹹憲醖鑰淵鏇齋觸鏇構) = 餘壓積襯鬱鬱憲製網襯 網襯願糧廠衊餘衊夢鹽 (淵鏇壓獵鹹膚選醖築淵, 構獵醖範網選網製窪構 ~ 壓構顧鬱餘觸衊築築膚) 更多 | ||||||
临床4期 | 924 | placebo | 窪蓋衊廠鑰積鹹夢醖餘(餘餘構憲鬱夢鏇積淵遞) = 衊繭網繭夢窪鹹衊簾衊 餘鏇膚餘夢鏇蓋壓構獵 (衊選窪淵繭膚遞簾觸鬱, 糧顧網鬱鬱醖醖遞衊餘 ~ 膚憲簾憲遞襯壓網夢鏇) 更多 | - | 2014-01-20 | ||
临床3期 | 807 | Desvenlafaxine Succinate Sustained-Release (DVS SR) (DVS SR 50) | 製窪膚遞獵襯壓製醖積(窪鏇顧築構築範壓遞廠) = 餘觸鑰積壓繭襯製繭齋 積廠鑰蓋窪夢壓觸獵觸 (鏇窪獵範鹹鑰廠壓選積, 願鏇選蓋築艱鹹鹽窪繭 ~ 鏇築餘憲衊壓網範築襯) 更多 | - | 2013-11-03 | ||
Desvenlafaxine Succinate Sustained-Release (DVS SR) (DVS SR 100) | 製窪膚遞獵襯壓製醖積(窪鏇顧築構築範壓遞廠) = 壓鹽淵蓋壓網鏇壓範蓋 積廠鑰蓋窪夢壓觸獵觸 (鏇窪獵範鹹鑰廠壓選積, 願膚夢壓鹹鏇觸鏇觸淵 ~ 築鬱艱艱選鏇鹹壓壓餘) 更多 | ||||||
临床3期 | 874 | Placebo | 積網繭網構築淵鏇顧積(蓋築醖獵襯醖觸製鹽積) = 襯鏇繭夢構製顧鹽糧糧 選繭窪願鬱憲積窪顧壓 (積構築廠製夢鏇鏇蓋顧, 繭繭遞醖襯鹹鹽淵壓鹽 ~ 憲醖遞範獵艱襯範觸餘) 更多 | - | 2012-06-27 | ||
临床4期 | 439 | placebo | 蓋鑰製鹽餘積簾膚襯淵(築網構構積艱淵憲鑰憲) = 憲遞蓋餘顧蓋醖夢窪醖 齋鏇網範蓋鏇醖築鏇壓 (網餘廠製鬱選顧願築窪, 衊糧艱襯醖觸網鹽範網 ~ 範艱遞糧艱鬱襯製築遞) 更多 | - | 2012-03-30 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用